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Background. When the bivalent and the quadrivalent HPV vaccines were marketed they were presented as having comparable
efficacy against cervical cancer. Differences between the vaccines are HPV types included and formulation of the adjuvant.Method.
A systematic review was conducted to assess the efficacy of the two vaccines against cervical cancer. Outcomes considered were
CIN2+, CIN3+, and AIS. Results. Nine reports (38,419 women) were included. At enrolment mean age of women was 20 years, 90%
had negative cytology, and 80% were seronegative and/or DNA negative for HPV 16 or 18 (na¨ıve women). In the TVC-na¨ıve, VE
against CIN2+ was 58% (95% CI: 35, 72); heterogeneity was detected, VE being 65% (95% CI: 54, 74) for the bivalent and 43% (95%
CI: 23, 57) for the quadrivalent. VE against CIN3+ was 78% (95% CI: <0, 97); heterogeneity was substantial, VE being 93% (95%
CI: 77, 98) for the bivalent and 43% (95% CI: 12, 63) for the quadrivalent. VE in the TVC was much lower. No sufficient data were
available on AIS. Conclusions. In na¨ıve girls bivalent vaccine shows higher efficacy, even if the number of events detected is low. In
women already infected the benefit of the vaccination seems negligible.
1. Introduction
In the seventies, Dr. Harald Zur Hausen firstly postulated the
link between human papillomaviruses (HPVs) and cervical
cancer: studies to develop an anticancer vaccine followed.
Approximately 70% of cervical cancers worldwide are asso-
ciated with two high-risk HPV types (16/18) [1, 2] and almost
90% of genital warts are associated with two low-risk HPV
types (6/11). Each year around 500,000 women develop inva-
sive cervical cancer worldwide, with 83% of new cases and
85% of deaths occurring in developing countries [3, 4]. Risk
factors associated with HPV infection are younger age at first
coitus, higher number of sexual partners, smoking cigarettes,
and history of herpes simplex virus infection [5, 6]. Some 75%
of sexually active women develop a HPV infection [7], more
frequently soon after their sexual debut: the majority of these
infections (between 70% and 90%) spontaneously clear [8–
10]. Aminority progress from acute infection to cervical can-
cer, a process taking decades and going through precancerous
lesions named cervical intraepithelial neoplasia (CIN) of
increasing severity, from CIN1 to CIN3; spontaneous regres-
sion of the lesions is possible at any point [4, 8]. Incidence of
genital warts is less precisely known, due to lack of data on the
general population, but it is estimated to be around 1% [8].
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Based on the results of five randomized controlled
trials (RCTs) involving 40,000 women [11–17] two HPV
vaccines entered themarket.Thequadrivalent vaccine against
HPV6/11/16/18 was approved by the FDA and the EMA in
2006 [18, 19], whereas the bivalent vaccine against HPV16/18
was first approved in Europe in 2007 [20] and then in the
USA in 2009 [21]. Soon after, several western countries such
as the USA, Australia, and five European states [22] started
national immunization campaigns targeting adolescent girls.
The number of countries adopting the vaccines has since
increased: in April 2014, 23 out of 29 European countries were
reported to have implemented it [23], budgetary constraints
being one relevant obstacle for the remaining countries. The
primary target of HPV vaccination is adolescent girls aged 11
to 13 years, with some minor differences in national recom-
mendations: in theUSA routine vaccination is recommended
at age 11 or 12 years with quadrivalent or bivalent vaccine for
females and with quadrivalent vaccine for males in a 3-dose
schedule during a 6-month interval [24]; in the UKHPV vac-
cine is recommended for girls under 15 years of age and con-
sists in two injections spaced at least six and notmore than 24
months apart.The vaccine is also recommended formenwho
have sex with men [25]. No prior assessment with Pap testing
or screening for existing HPV infection is required.
Both vaccines contain human papillomavirus L1 self-
assembling virus-like particles and are not infectious. Dif-
ferences between the two vaccines are the number of HPV
types included and formulation of the adjuvant (Table 1)
possibly leading to different vaccine efficacy (VE) [36–38].
Head-to-head comparisons between the two vaccines are still
exclusively based on immunogenicity [38, 39], although an
immune correlate of protection has not yet been established
[40].
Three meta-analyses, published when vaccines were mar-
keted, showed comparably high efficacy of the two vaccines
against precancerous lesions associated with HPV16/18 [30,
41, 42]. The meta-analyses subsequently published [43, 44]
have confirmed the high efficacy of the vaccines against
lesions associated with HPV16/18, but they did not provide
information about VE against any cervical lesions irrespec-
tive of HPV type, nor did they discuss possible differences
in terms of efficacy of the two vaccines. Thus, our systematic
review that includes studies with longer follow-up aims to
assess differences between the two vaccines from a public
health perspective, considering all cervical lesions.
2. Methods
The systematic review was developed based on a prespeci-
fied protocol (protocol number FARM8N2ZFL) funded by
the Italian Medicines Agency (AIFA) within a program of
independent research on drugs [45].The PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses)
statement guided the content and reporting of the review
[46]. Published and unpublished RCTs comparing any of the
two HPV vaccines versus placebo or any other control were
considered for inclusion. We exclusively considered studies
involving women, irrespective of age at enrolment.
As for protocol, primary outcomemeasures were cervical
lesions (i.e., cervical cancer, CIN2, CIN3, and AIS) associated
with anyHPV type and cervical lesions exclusively associated
with HPV16/18 occurring in three study populations: accord-
ing to protocol population (ATP), the general population
of vaccinated women (total vaccine cohort (TVC)) approx-
imating all women regardless of status of HPV infection at
vaccination, and a selected population ofwomen seronegative
for HPV16/18 and HPV DNA negative for 14 oncogenic HPV
types, approximating the group of young adolescent girls tar-
geted in the national immunization campaigns (TVC-na¨ıve).
In this paper only data related to cervical lesions associated
with any HPV type occurring in the TVC and in the TVC-
na¨ıve population are reported, as the other data are not
relevant from a public health perspective.
2.1. Literature Search. Trial identification: we searched the
Cochrane Library (to Issue 3, 2014), MEDLINE (to March
2014), and EMBASE (to March 2014) using keywords and
MeSH terms as reported in Annex 1 online, in combination
with a highly sensitive filter for identifying RCT [47]. There
were no language or time restrictions. Reference lists of rele-
vant papers were also examined to identify additional studies.
For unpublished RCTs, we searched the Internet for pre-
publication study presentations at conferences or meetings.
Moreover experts in the field and vaccinemanufacturers were
contacted for further information (unpublished studies and
single patient data). Clinical trial registers were searched for
ongoing studies. Two review authors independently screened
abstracts of potential studies and retrieved full articles for
those deemed eligible.
2.2. Study Selection. Two reviewers carried out independent
assessment of citations retrieved. When more than one
publication reported the same trial, the one with a longer
follow-up was selected. Reasons for exclusion were recorded.
Quality of trials was assessed using the criteria outlined in
the Cochrane Handbook [47] and included the assessment of
(i) generation of the randomization sequence, (ii) quality of
the allocation concealment, (iii) completeness of follow-up,
and (iv) blinding of the outcome assessment. Based on quality
assessment the risk of bias of the included trials was defined
as low, high, or unclear. Differences in opinion were resolved
through discussion involving a third author if needed.
2.3. Statistical Analysis. Two review authors extracted the
data independently using a data extraction form. Statistical
analyses were carried out using the STATA software version
11. For time to event data the hazard ratio (HR) was used as a
measure of association.The resultswere summarized by using
the inverse of variancemethod and the random effectsmodel.
Point estimates as well as their 95% confidence intervals
(95% CI) were calculated and represented by the forest plot.
Vaccine efficacy (VE) was calculated as VE(%) = (RU −
RV)/RU×100, where RU is the rate of disease in the unvacci-
nated and RV is the rate in the vaccinated [48]. The equation
can be rewritten to use the HR in the following way: VE(%) =
(1 −HRv/u) × 100, where HRv/u is the HR of the vaccinated
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Table 1: Characteristics of bivalent and quadrivalent HPV vaccine.
Quadrivalent vaccine Bivalent vaccine
Commercial name Gardasil/Silgard Cervarix
Manufacturer Sanofi Pasteur MSD SNC GlaxoSmithKline Biologicals S.A.
HPV types
HPV 6 L1 protein 20 𝜇g HPV 16 L1 protein 20 𝜇g
HPV 11 L1 protein 40𝜇g HPV18 L1 protein 20 𝜇g
HPV 16 L1 protein 40 𝜇g
HPV 18 L1 protein 20𝜇g
Common characteristics L1 protein in the form of noninfectious virus-like particles produced by recombinant DNA technology
Differences in cellular
culture
Yeast cells (Saccharomyces cerevisiae
CANADE 3C-5 (strain 1895))
Hi-5 Rix4446 cells derived from
Trichoplusia ni using a Baculovirus
expression system
Differences in adjuvant
Amorphous aluminium
hydroxyphosphate sulfate adjuvant,
225 𝜇g
AS04 adjuvant system composed of
aluminium hydroxide and
3-O-desacyl-4󸀠-monophosphoryl lipid
A, 50 𝜇g
Therapeutic indications
Gardasil is a vaccine for use from the
age of 9 years for the prevention of
(i) premalignant genital lesions
(cervical, vulvar, and vaginal) and
cervical cancer causally related to
certain oncogenic human
papillomavirus (HPV) types;
(ii) genital warts (condyloma
acuminata) causally related to specific
HPV types.
Cervarix is a vaccine for use from the
age of 9 years for the prevention of
(i) premalignant cervical lesions and
cervical cancer causally related to
certain oncogenic human
papillomavirus (HPV) types.
Efficacy data leading to
registration 95.2% (87.2, 98.7)
1 90.4% (53.4, 99.3)
Efficacy data in the latest
publication 43% (13, 63)
3 93% (79, 99)4
Mean follow-up of phase III
trials 3.6 years
1 4 years2
1Vaccine efficacy against CIN/AIS associated with vaccine related HPV in the TVC-na¨ıve from EMA registration data [19].
2Vaccine efficacy against CIN2+ associated with vaccine related HPV in the TVC-na¨ıve from EMA registration data [20].
3Vaccine efficacy against any CIN3 in the TVC-naı¨ve fromMun˜oz et al. 2010 [26].
4Vaccine efficacy against any CIN3+ in the TVC-naı¨ve from Lehtinen et al. 2012 [27].
versus the unvaccinated. Heterogeneity among studies was
assessed using the 𝐼2 statistics [47].
2.4. Subgroup Analyses. The following prespecified subgroup
analyses were planned:
(i) Geographical areas (Europe, Africa, Asia, North
America, and South and Central America): the litera-
ture suggests that prevalence and circulation of HPV
high risk types varies according to geographical areas
[49–51].
(ii) Vaccine type (bivalent, quadrivalent): data on VE can
be influenced by type of vaccine used as differences
between the two formulations could be not negligible.
3. Results
3.1. Selection of Studies. Study identification and selection
process is outlined in Figure 1. Of the 726 records initially
identified, 3 were duplicates and 670 were excluded based on
title and abstract assessment. The most common reasons for
exclusion were the following: reports were not RCTs, did not
assess the outcome of interest, were not related to oncogenic
HPV or to vaccine administration, or were studies reporting
exclusively laboratory or immunogenicity data. We assessed
the full text of 53 articles and excluded 44 (reasons reported
in Figure 1).Thus nine reports [26–29, 31–35], corresponding
to five registered protocols [52–56], were included in the
systematic review: in three trials (20,797 women) the bivalent
vaccine was used (PATRICIA trial being the larger study)
[27–29] and in two trials (17,622 women) the quadrivalent
vaccine was assessed (FUTURE I and FUTURE II trials)
[26]. Five publications reporting subset of data of the above-
mentioned trials relating to specific geographical areas were
also included [31–35].
The data of the phase III trials included in our meta-
analysis have amean follow-up of 4 years for the bivalent trial
[27] and 3.6 years for the quadrivalent trial [26], longer than
that of the systematic reviews with meta-analysis published
up to now.
4 Journal of Immunology Research
Records identified from
bibliographic databases
n = 726
Duplicate records removed
manually
n = 3
Records screened for eligibility
(full-text article)
n = 53
Reports included in systematic review
n = 9 [43–51]
corresponding to 5 RCTs
Excluded based on
title and abstract assessment
n = 670
Excluded
n = 44
(i) Outcomes not relevant, 29
(ii) Subgroups analysis not relevant, 4
(iii) Included in subsequent follow-up studies, 4
(iv) Cohort studies, 2
(v) Not providing raw data, 1
(vi) Monovalent vaccine, 1
(vii) Not randomized study, 1
(viii) Not controlled trial, 1
(ix) Comparing DTP and Polio coadministration, 1
Figure 1: Study selection flowchart.
3.2. Quality of Included Trials and Characteristics of Trial
Participants. Characteristics of the trials are summarized in
Table 2.
Studies were all double blind RCTs, with an adequate
sample size. They were all manufacturer-sponsored. Eligible
participants were healthy, not pregnant women aged between
15 and 26 years, with 6 or less lifetime sexual partners and
no history of abnormal Pap smear at enrolment. Almost 90%
of women had normal cytology at study entry. Risk of bias
was low in 4 out of 5 trials: generation of the randomization
sequence, quality of allocation concealment, completeness
of follow-up, and blinding of outcome assessment were
adequate. Risk of bias was unclear (generation of the ran-
domization sequence and allocation concealment were not
described) in one smaller trial conducted in Japan [29]; as
the Japanese trial provided only data on CIN2+ lesions exclu-
sively associated with HPV16/18, its results are not reported
here. Characteristics of the women enrolled in the trials used
in this meta-analysis are reported in Table 3.
3.3. Pooling of the Data. Pooling of the data was possible for
CIN2+ [26–28], CIN3+ [26, 27], and AIS [26, 28]. Data for
each outcome are presented below for the TVC and the TVC-
na¨ıve cohorts.
CIN2+. The pooled HRs for CIN2+ lesions associated with
any type of HPV in the TVC and in the TVC-na¨ıve are
reported in Figure 2. Corresponding values of VE were 26%
(95% CI: 11, 39) in the TVC [26, 27] and 58% (95% CI: 35,
72) in the TVC-naı¨ve [26–28]. Results suggested substantial
heterogeneity among bivalent and quadrivalent vaccines: 𝐼2
test was 68.7% and 66.4% in the TVC and in the TVC-na¨ıve,
respectively.
CIN3+. The pooled HRs for CIN3+ lesions associated with
any type of HPV in the TVC and in the TVC-na¨ıve are
reported in Figure 3. Corresponding values of VE were 32%
(95% CI: <0, 56) in the TVC [26, 27] and 78% (95% CI: <0,
97) in the TVC-naı¨ve [26, 27]. Results suggested substantial
heterogeneity among bivalent and quadrivalent vaccines: 𝐼2
test was 86.3% and 90.7% in the TVC and in the TVC-na¨ıve,
respectively.
AIS. The pooled HR for lesions associated with any type
of HPV was 0.31 (95% CI: 0.14–0.70) in the TVC [26, 27],
corresponding values of VE being 69% (95% CI: 30, 86).
AIS cases in the TVC-naı¨ve cohort were zero in the vac-
cine group and ten in the placebo; thus only an approximate
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PATRICIA
Overall (I2 = 68.7%, p = 0.074)
Note: weights are from random effects analysis
Treatment
n/N n/N
Control
287/8694
421/8562
428/8708
520/8598
0.5 0.75 1
Favours experimental Favours control
HR (95% CI) Weight (%)
0.67 (0.57, 0.78)
0.81 (0.71, 0.93)
0.74 (0.61, 0.89)
47.92
52.08
100.00
FUTURE I + II
(a)
Note: weights are from random effects analysis
Favours experimental Favours control
Study Treatment
n/N n/N
Control HR (95% CI) Weight (%)
Bivalent
GSK
Subtotal (I2 = 0.0%, p = 0.713)
Quadrivalent
Subtotal (I2 = 0.0%, p = 0.0)
Overall (I2 = 66.4%, p = 0.051)
5/505
61/5466
17/497
172/5452
0.28 (0.09, 0.88)
0.35 (0.26, 0.47)
0.35(0.26, 0.46)
0.57 (0.43, 0.77)
0.57 (0.43, 0.77)
0.42 (0.28, 0.65)
11.04
44.48
55.52
44.48
44.48
100.00
0.25 0.5 1 2
PATRICIA
77/4616 136/4680FUTURE I + II
(b)
Figure 2: Vaccine efficacy against CIN2+ lesions, in total vaccine (a) and total vaccine naı¨ve cohort (b), any HPV type.
estimate of the efficacy was possible. The pooled HR for
lesions associated with any type of HPV was 0.01 (95% CI:
0.01–0.22) resulting in a VE of 99% (95% CI: 78, 99) [26, 27].
For all the comparisons 𝐼2 suggested low heterogeneity.
3.4. Analysis by Geographical Area. Although formally
required by the scientific advisory unit of ECDC in
Stockholm, the two manufacturers did not provide single
patient data (the authors received only partial data unsuitable
for the analysis from GSK and no answer at all from Sanofi
Pasteur MSD).
Five published papers [31–35] reported data according to
geographical areas. Pooling of the data was not appropriate
since geographical areas definition differed (Table 4).
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Study Treatment
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Favours experimental Favours control
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PATRICIA
Overall (I2 = 86.3%, p = 0.007)
Note: weights are from random effects analysis
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0.84 (0.71, 1.01)
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47.16
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100.00
FUTURE I + II
(a)
Study Treatment
n/N n/N
Control HR (95% CI) Weight (%)
Favours experimental Favours control
0.25 0.50.05 10.10.01 42
PATRICIA
Overall (I2 = 90.7%, p = 0.001)
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Figure 3: Vaccine efficacy against CIN3+ lesions, in total vaccine (a) and total vaccine naı¨ve cohort (b), any HPV type.
4. Discussion
Since their introduction into the market, the effectiveness
of the two vaccines against cervical cancer, based on first
published data [11–17], has been subject of debate. Enthu-
siastic positions assumed that if vaccines are immunogenic
and prevent infections associated with HPV16/18 they also
prevent cervical cancer and therefore should be widely used
[57–59]. Uncertainty was related to the following issues:
correlation between immune response and clinical outcomes,
need for a booster dose, replacement with other oncogenic
strains, and possible reduction of Pap-test screening among
the vaccinated [60–65].
Our systematic review highlights that, for precancerous
lesions (CIN), the only available proxy of cervical cancer and
heterogeneity among pooled studies is substantial (Figures
2 and 3): the bivalent vaccine shows higher efficacy against
precancerous lesions. We focus our comments on the TVC-
na¨ıve cohort, asVE in the TVC is confirmed to bemuch lower
and HPV vaccination is not universally offered to women
already sexually active and data onAIS are too sparse tomake
sensible comments. For CIN2+ lesions estimates of efficacy of
the two vaccines in the TVC-naı¨ve cohort differ but the wide
limits of the confidence intervals partially overlap (VE 65%;
95% CI: 54, 74 for the bivalent and VE 43%; 95% CI: 23, 57
for the quadrivalent), whereas for CIN3+ lesions estimates
of efficacy largely differ and the limits of the confidence
intervals do not overlap (VE 93%; 95% CI: 77, 98 for the
bivalent and VE 43%; 95% CI: 12, 63 for the quadrivalent).
However, due to limited number of patients with lesions
detected, leading to wide confidence intervals of our esti-
mates of effect, our conclusions should be interpreted with
caution. The heterogeneity observed might be due to higher
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efficacy of the bivalent vaccine against cervical cancer pos-
sibly related to the specific adjuvant used (ASO4 adjuvant
system), as suggested in two recent immune response head-
to-head studies that consistently showed a higher neutral-
izing antibody production [38, 39] and a higher CD4+ T
cell response [38] in bivalent than in quadrivalent vaccine
recipients. Heterogeneity can also be due to baseline differ-
ences between the populations enrolled in the two trials,
although such differences were not reported in the two trials
(Table 3). However, misclassification of na¨ıve women cannot
be ruled out since the two manufacturers used different
laboratory tests to measure immune response and to identify
na¨ıve girls. In fact cLIA test was used in the FUTURE trials
whereas ELISA test that has a higher sensitivity than cLIA
[66] was used in the PATRICIA trial.Moreover, data are often
differently and poorly reported in the published trials [26–29,
31–35]; thus our ability to make meaningful comparisons and
further analysis (e.g., assess the possible effect modification
by smoking status or age) is hindered. We asked the manu-
facturers to provide individual patient data, but we did not
receive a positive answer.
Another relevant point is that the length of the follow-
up in the trials assessed seems insufficient to detect infor-
mation relevant to the public and to policy-makers: as time
interval from HPV infection to cervical cancer development
is approximately 20 years, all information gathered in a much
shorter period of time is not conclusive. Nevertheless the
PATRICIA trial has a planned follow-up of 4 years [27] and
longer follow-up data on bivalent vaccine are only available
for 436 Brazilian women enrolled in a previous phase II trial
[67].Wewill havemore information in 2020, when the results
of the Finnish study that extended the follow-up for Finnish
girls enrolled in the PATRICIA study will be published [68]
and when the extension studies for the FUTURE II trial
assessing the quadrivalent vaccine will also be available. In
the meantime an open debate in this respect is urgently
needed: national health agencies should set up a surveillance
system to provide data on actual vaccines efficacy in the field
and to allow international comparisons. At the moment, this
comparison is not possible and we still do not know how
to choose between the two vaccines [69]. Contrary to what
is previously reported in other meta-analyses [30, 41–44],
our systematic review suggests that the quadrivalent and the
bivalent vaccines differ in terms of efficacy. This could be
attributable to the different adjuvants contained in the two
vaccines. Such difference in efficacy has not been widely
recognized by national health agencies. For example, in Italy
HPV vaccines are chosen and purchased through tendering
schemes organized by regional health authorities that are
based on the lowest price [70].
Apart from cervical cancer prevention, quadrivalent vac-
cine is known to effectively prevent genital warts [71, 72],
whereas the bivalent vaccine can only marginally impact on
these benign but distressing lesions [73]. The UK and a few
Italian regions have recently substituted the bivalent with the
quadrivalent vaccine, assuming comparable efficacy of the
two vaccines against cervical cancer and giving an additional
value to the activity against genital warts of the quadrivalent
vaccine [10, 74]. Unfortunately, it is not possible to anticipate
the consequences of the UK’s and Italian choice: if different
vaccine efficacy of the bivalent and the quadrivalent vaccine is
going to be confirmed, lack of equivalence in terms of cervical
cancer prevention could become an issue. The availability in
the coming years of new broader spectrumHPVprophylactic
vaccines could provide more insight into the current debate
[75, 76].
5. Conclusions
In conclusion,we acknowledge that this systematic reviewhas
some limitations due to a low number of women with events
and a high heterogeneity among trials that suggest caution
in the interpretation of results. However, our conclusions
are consistent with those from recent immunogenicity head-
to-head studies [38, 39] and that provides strength to our
interpretation. Our systematic review suggests that after nine
years since HPV vaccines were introduced, their estimates of
efficacy seem to diverge over time. The decision to consider
the two vaccines similar in terms of cervical cancer preven-
tion seems challenged by our longer term follow-up analy-
ses. This might have implications for policy and pragmatic
choices and deserves an open and comprehensive discussion.
Moreover, international comparisons of the actual effective-
ness of the two vaccines used in the field can add valuable
information.
Finally, regulatory agencies should encourage the phar-
maceutical companies to provide data across trials to assess
all relevant outcomes in a comparable way, to reduce uncer-
tainty, and to support health policy-makers that have to
choose between alternative options [77, 78].
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